Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.
暂无分享,去创建一个
[1] Lawrence Corey,et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] M. Boeckh,et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. , 2002, The Journal of infectious diseases.
[3] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Wingard,et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital , 2002, Bone Marrow Transplantation.
[5] J. Perfect,et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] G. Wilkinson,et al. Cytomegalovirus: from evasion to suppression? , 2001, Nature Immunology.
[7] M. Remberger,et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. , 2001, Blood.
[8] M. Boeckh,et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. , 2001, Blood.
[9] R. Storb,et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. , 2001, Blood.
[10] J. Baddley,et al. Invasive mold infections in allogeneic bone marrow transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] S. Ellermann-Eriksen,et al. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii , 2001, Clinical and experimental immunology.
[12] R Storb,et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.
[13] A. Fauser,et al. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study , 2001, Bone Marrow Transplantation.
[14] M. Boeckh,et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.
[15] A. Fauser,et al. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study , 2000, Bone Marrow Transplantation.
[16] S. Singhal,et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial , 2000, The Lancet.
[17] V. Kuenen-Boumeester,et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.
[18] H. Einsele,et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection , 2000, Bone Marrow Transplantation.
[19] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[20] J. Latgé,et al. Aspergillus fumigatus and Aspergillosis , 1999, Clinical Microbiology Reviews.
[21] M. Boeckh,et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. , 1999, Blood.
[22] J. Latgé,et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] A. Mencacci,et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. , 1998, The Journal of infectious diseases.
[24] C Anasetti,et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.
[25] A. Mehta,et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Snydman,et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. , 1997, The American journal of medicine.
[27] W. Leisenring,et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.
[28] E. Jantunen,et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients , 1997, Bone Marrow Transplantation.
[29] J. Latgé,et al. Th1 and Th2 cytokines in mice with invasive aspergillosis , 1997, Infection and immunity.
[30] M. Boeckh,et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.
[31] J. Fay,et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.
[32] R. Storb,et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.
[33] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[34] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[35] L. Kobzik,et al. Alteration of pulmonary macrophage function by respiratory syncytial virus infection in vitro. , 1995, Journal of immunology.
[36] R. Clift. Marrow transplantation for chronic myeloid leukemia. , 1995, Cancer treatment and research.
[37] V. Morrison,et al. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. , 1994, The American journal of medicine.
[38] S. Riddell,et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.
[39] Lloyd D. Fisher,et al. 2. Biostatistics: A Methodology for the Health Sciences , 1994 .
[40] E. Michaliszyn,et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages , 1993, Infection and immunity.
[41] F. Derouin,et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. , 1993, Bone marrow transplantation.
[42] L. Fisher,et al. Biostatistics: A Methodology for the Health Sciences , 1993 .
[43] J. Armitage,et al. Nosocomial Invasive Aspergillosis in Lymphoma Patients Treated with Bone Marrow or Peripheral Stem Cell Transplants , 1993, Infection Control & Hospital Epidemiology.
[44] K. Sullivan,et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.
[45] R. Storb,et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. , 1991, Bone marrow transplantation.
[46] W. Stephenson. Institutional animal care and use committees and the moderate position. , 1991, Between the species : a journal of ethics.
[47] J. Wingard,et al. Aspergillus infections in bone marrow transplant recipients. , 1987, Bone marrow transplantation.
[48] M. Mandel. Infectious complications of human bone marrow transplantation , 1981 .
[49] Thomas,et al. Defective neutrophil chemotaxis in bone marrow transplant patients. , 1976, The Journal of clinical investigation.
[50] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .